These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11823113)

  • 1. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate.
    Luef G; Abraham I; Trinka E; Alge A; Windisch J; Daxenbichler G; Unterberger I; Seppi K; Lechleitner M; Krämer G; Bauer G
    Epilepsy Res; 2002 Jan; 48(1-2):91-102. PubMed ID: 11823113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.
    Isojärvi JI; Rättyä J; Myllylä VV; Knip M; Koivunen R; Pakarinen AJ; Tekay A; Tapanainen JS
    Ann Neurol; 1998 Apr; 43(4):446-51. PubMed ID: 9546324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women.
    Luef G; Abraham I; Haslinger M; Trinka E; Seppi K; Unterberger I; Alge A; Windisch J; Lechleitner M; Bauer G
    J Neurol; 2002 Jul; 249(7):835-41. PubMed ID: 12140666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy.
    Stephen LJ; Kwan P; Shapiro D; Dominiczak M; Brodie MJ
    Epilepsia; 2001 Aug; 42(8):1002-6. PubMed ID: 11554885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered ovarian function and cardiovascular risk factors in valproate-treated women.
    Isojärvi JI; Taubøll E; Pakarinen AJ; van Parys J; Rättyä J; Harbo HF; Dale PO; Fauser BC; Gjerstad L; Koivunen R; Knip M; Tapanainen JS
    Am J Med; 2001 Sep; 111(4):290-6. PubMed ID: 11566460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The dangers of valproate in women].
    Isojärvi J
    Duodecim; 1998; 114(9):825, 827. PubMed ID: 11524801
    [No Abstract]   [Full Text] [Related]  

  • 7. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy.
    El-Khayat HA; Abd El-Basset FZ; Tomoum HY; Tohamy SM; Zaky AA; Mohamed MS; Hakky SM; El Barbary NS; Nassef NM
    Epilepsia; 2004 Sep; 45(9):1106-15. PubMed ID: 15329076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy.
    Luef G; Abraham I; Hoppichler F; Trinka E; Unterberger I; Bauer G; Lechleitner M
    Metabolism; 2002 Oct; 51(10):1274-8. PubMed ID: 12370846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases.
    Isojarvi JI; Tapanainen JS
    Arch Neurol; 2000 Jul; 57(7):1064-8. PubMed ID: 10891991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study.
    Sidhu HS; Srinivasa R; Sadhotra A
    Epilepsy Res; 2018 Jan; 139():20-27. PubMed ID: 29144993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy.
    Hu X; Wang J; Dong W; Fang Q; Hu L; Liu C
    Epilepsy Res; 2011 Nov; 97(1-2):73-82. PubMed ID: 21820873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and endocrine disorders in women taking valproate for epilepsy.
    Isojärvi JI; Laatikainen TJ; Knip M; Pakarinen AJ; Juntunen KT; Myllylä VV
    Ann Neurol; 1996 May; 39(5):579-84. PubMed ID: 8619542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of insulin secretion in Valproate-treated patients with epilepsy.
    Pylvänen V; Pakarinen A; Knip M; Isojärvi J
    Epilepsia; 2006 Sep; 47(9):1460-4. PubMed ID: 16981861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
    Pylvänen V; Pakarinen A; Knip M; Isojärvi J
    Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate clinical management of women taking valproate.
    Piontek CM; Wisner KL
    J Clin Psychiatry; 2000 Mar; 61(3):161-3. PubMed ID: 10817097
    [No Abstract]   [Full Text] [Related]  

  • 16. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy.
    Isojärvi JI; Laatikainen TJ; Pakarinen AJ; Juntunen KT; Myllylä VV
    N Engl J Med; 1993 Nov; 329(19):1383-8. PubMed ID: 8413434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the association between valproate and polycystic ovary syndrome.
    Genton P; Bauer J; Duncan S; Taylor AE; Balen AH; Eberle A; Pedersen B; Salas-Puig X; Sauer MV
    Epilepsia; 2001 Mar; 42(3):295-304. PubMed ID: 11442143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate, bipolar disorder and polycystic ovarian syndrome.
    McIntyre RS; Mancini DA; McCann S; Srinivasan J; Kennedy SH
    Bipolar Disord; 2003 Feb; 5(1):28-35. PubMed ID: 12656935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting serum insulin and lipid levels in men with epilepsy.
    Pylvänen V; Knip M; Pakarinen AJ; Turkka J; Kotila M; Rättyä J; Myllylä VV; Isojärvi JI
    Neurology; 2003 Feb; 60(4):571-4. PubMed ID: 12601094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries.
    Soares JC
    Bipolar Disord; 2000 Mar; 2(1):37-41. PubMed ID: 11254018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.